A/Prof Steven David
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
44 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Intraoperative radiation therapy delivered at the time of lumpectomy for treatment of early-stage breast cancer: Median five-year follow-up outcomes of the single-arm, prospective, multi-institution ExBRT trial
DOI: 10.1016/j.soi.2026.1002712026
Journal article
Real-World Endpoints in Stereotactic Body Radiation Therapy Trials for Oligoprogression: Beyond Progression-Free Survival and Overall Survival
DOI: 10.1016/j.ijrobp.2025.08.0092026
Journal article
Case Report: Serial stereotactic radiotherapy in lieu of systemic therapy change for oligoprogressive breast cancer: eight courses to 17 metastases
DOI: 10.3389/fonc.2026.16418762025
Journal article
Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors
DOI: 10.1016/j.breast.2025.1045862025
Journal article
Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor–Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial
DOI: 10.1200/oa-25-000312025
Conference Proceedings
Evaluating the impact of a tertiary multidisciplinary meeting in metastatic breast cancer: A prospective study
DOI: 10.1016/j.breast.2024.1038612024
Journal article
Sustained lymphocyte decreases after treatment for early breast cancer
DOI: 10.1038/s41523-024-00698-4
RECENT SCHOLARLY WORKS
2024
Journal article
Impact of multidisciplinary team meetings on the management of patients with breast cancer in a large private healthcare facility
DOI: 10.1111/ajco.139472023
Journal article
Stereotactic Ablative Body Radiotherapy (SABR) for Oligoprogressive ER-Positive Breast Cancer (AVATAR): A Phase II Prospective Multicenter Trial
DOI: 10.1016/j.ijrobp.2023.08.0332023
Conference Proceedings
Association between baseline radiological tumor burden and outcomes in patients with metastatic breast cancer treated with an immune checkpoint inhibitor
DOI: 10.1200/jco.2023.41.16_suppl.1103